#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Early diagnosis and treatment of human malaria reduces disease , prevents deaths , and contributes to reduced transmission .
3-1	17-22	Early	event[3]|event[4]	new[3]|new[4]	coref|coref|coref|coref	6-13[41_3]|15-15[151_4]|6-13[41_3]|15-15[151_4]
3-2	23-32	diagnosis	event[3]|event[4]	new[3]|new[4]	_	_
3-3	33-36	and	event[4]	new[4]	_	_
3-4	37-46	treatment	event[4]|event[5]	new[4]|new[5]	_	_
3-5	47-49	of	event[4]|event[5]	new[4]|new[5]	_	_
3-6	50-55	human	event[4]|event[5]|abstract[6]	new[4]|new[5]|new[6]	coref	4-6[0_6]
3-7	56-63	malaria	event[4]|event[5]|abstract[6]	new[4]|new[5]|new[6]	_	_
3-8	64-71	reduces	_	_	_	_
3-9	72-79	disease	event	new	coref	11-5
3-10	80-81	,	_	_	_	_
3-11	82-90	prevents	_	_	_	_
3-12	91-97	deaths	event	new	_	_
3-13	98-99	,	_	_	_	_
3-14	100-103	and	_	_	_	_
3-15	104-115	contributes	_	_	_	_
3-16	116-118	to	_	_	_	_
3-17	119-126	reduced	abstract[9]	new[9]	coref	8-24[0_9]
3-18	127-139	transmission	abstract[9]	new[9]	_	_
3-19	140-141	.	_	_	_	_

#Text=Detection of antibody response against malaria antigens is often done through Enzyme-Linked Immunosorbent Assay ( ELISA ) ; many of these diagnostic assays are designed with a single antigen or with recombinant antigens of different stages of the parasites ( tissue infection or blood ) , where merozoite surface proteins can be detected , and have demonstrated good sensitivity and specificity .
4-1	142-151	Detection	abstract[10]	new[10]	_	_
4-2	152-154	of	abstract[10]	new[10]	_	_
4-3	155-163	antibody	abstract[10]|substance|abstract[12]	new[10]|new|new[12]	coref|coref	6-27|6-27
4-4	164-172	response	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-5	173-180	against	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-6	181-188	malaria	abstract[10]|abstract[12]|abstract|substance[14]	new[10]|new[12]|giv|new[14]	coref|coref|coref|coref	4-32[21_14]|6-16|4-32[21_14]|6-16
4-7	189-197	antigens	abstract[10]|abstract[12]|substance[14]	new[10]|new[12]|new[14]	_	_
4-8	198-200	is	_	_	_	_
4-9	201-206	often	_	_	_	_
4-10	207-211	done	_	_	_	_
4-11	212-219	through	_	_	_	_
4-12	220-233	Enzyme-Linked	event|abstract[17]	new|new[17]	appos|appos	4-16[0_17]|4-16[0_17]
4-13	234-247	Immunosorbent	abstract|abstract[17]	new|new[17]	_	_
4-14	248-253	Assay	abstract[17]	new[17]	_	_
4-15	254-255	(	_	_	_	_
4-16	256-261	ELISA	abstract	giv	coref	6-8
4-17	262-263	)	_	_	_	_
4-18	264-265	;	_	_	_	_
4-19	266-270	many	_	_	_	_
4-20	271-273	of	_	_	_	_
4-21	274-279	these	abstract[19]	new[19]	_	_
4-22	280-290	diagnostic	abstract[19]	new[19]	_	_
4-23	291-297	assays	abstract[19]	new[19]	_	_
4-24	298-301	are	_	_	_	_
4-25	302-310	designed	_	_	_	_
4-26	311-315	with	_	_	_	_
4-27	316-317	a	object[20]	new[20]	_	_
4-28	318-324	single	object[20]	new[20]	_	_
4-29	325-332	antigen	object[20]	new[20]	_	_
4-30	333-335	or	_	_	_	_
4-31	336-340	with	_	_	_	_
4-32	341-352	recombinant	substance[21]	giv[21]	coref	7-5[72_21]
4-33	353-361	antigens	substance[21]	giv[21]	_	_
4-34	362-364	of	substance[21]	giv[21]	_	_
4-35	365-374	different	substance[21]|abstract[22]	giv[21]|new[22]	_	_
4-36	375-381	stages	substance[21]|abstract[22]	giv[21]|new[22]	_	_
4-37	382-384	of	substance[21]|abstract[22]	giv[21]|new[22]	_	_
4-38	385-388	the	substance[21]|abstract[22]|animal[23]	giv[21]|new[22]|new[23]	appos	4-41[26_23]
4-39	389-398	parasites	substance[21]|abstract[22]|animal[23]	giv[21]|new[22]|new[23]	_	_
4-40	399-400	(	_	_	_	_
4-41	401-407	tissue	object|abstract[25]|animal[26]	new|new[25]|giv[26]	coref|coref|coref|coref|coref|coref	6-37[49_25]|6-62[57_26]|6-37[49_25]|6-62[57_26]|6-37[49_25]|6-62[57_26]
4-42	408-417	infection	abstract[25]|animal[26]	new[25]|giv[26]	_	_
4-43	418-420	or	animal[26]	giv[26]	_	_
4-44	421-426	blood	animal[26]|substance	giv[26]|new	coref	5-18[37_0]
4-45	427-428	)	_	_	_	_
4-46	429-430	,	_	_	_	_
4-47	431-436	where	_	_	_	_
4-48	437-446	merozoite	abstract|object[30]	new|new[30]	_	_
4-49	447-454	surface	place|object[30]	new|new[30]	_	_
4-50	455-463	proteins	object[30]	new[30]	_	_
4-51	464-467	can	_	_	_	_
4-52	468-470	be	_	_	_	_
4-53	471-479	detected	_	_	_	_
4-54	480-481	,	_	_	_	_
4-55	482-485	and	_	_	_	_
4-56	486-490	have	_	_	_	_
4-57	491-503	demonstrated	_	_	_	_
4-58	504-508	good	abstract[31]	new[31]	_	_
4-59	509-520	sensitivity	abstract[31]	new[31]	_	_
4-60	521-524	and	_	_	_	_
4-61	525-536	specificity	abstract	new	_	_
4-62	537-538	.	_	_	_	_

#Text=However , many individuals cannot be easily diagnosed due to the low levels of antibodies present in their blood .
5-1	539-546	However	_	_	_	_
5-2	547-548	,	_	_	_	_
5-3	549-553	many	person[33]	new[33]	ana	5-18[0_33]
5-4	554-565	individuals	person[33]	new[33]	_	_
5-5	566-572	cannot	_	_	_	_
5-6	573-575	be	_	_	_	_
5-7	576-582	easily	_	_	_	_
5-8	583-592	diagnosed	_	_	_	_
5-9	593-596	due	_	_	_	_
5-10	597-599	to	_	_	_	_
5-11	600-603	the	abstract[34]	new[34]	_	_
5-12	604-607	low	abstract[34]	new[34]	_	_
5-13	608-614	levels	abstract[34]	new[34]	_	_
5-14	615-617	of	abstract[34]	new[34]	_	_
5-15	618-628	antibodies	abstract[34]|substance	new[34]|new	coref	7-3[70_0]
5-16	629-636	present	_	_	_	_
5-17	637-639	in	_	_	_	_
5-18	640-645	their	person|substance[37]	giv|giv[37]	coref|coref	6-31[47_0]|6-31[47_0]
5-19	646-651	blood	substance[37]	giv[37]	_	_
5-20	652-653	.	_	_	_	_

#Text=In this context , the use of ELISA as a tool for laboratory diagnosis of malaria has some limitations , namely : ( i ) low antibody titres presented by individuals in the acute phase of infection ; ( ii ) many Plasmodium sp . are involved in human malaria ; ( iii ) different evolutionary forms of Plasmodium spp. during infection and life cycle ; and ( iv ) different resistance and susceptibility profiles during infection , and consequently in the immunity profile against malaria parasites .
6-1	654-656	In	_	_	_	_
6-2	657-661	this	abstract[38]	new[38]	_	_
6-3	662-669	context	abstract[38]	new[38]	_	_
6-4	670-671	,	_	_	_	_
6-5	672-675	the	abstract[39]	new[39]	coref	8-17[86_39]
6-6	676-679	use	abstract[39]	new[39]	_	_
6-7	680-682	of	abstract[39]	new[39]	_	_
6-8	683-688	ELISA	abstract[39]|abstract	new[39]|giv	coref	14-20[138_0]
6-9	689-691	as	abstract[39]	new[39]	_	_
6-10	692-693	a	abstract[39]	new[39]	_	_
6-11	694-698	tool	abstract[39]	new[39]	_	_
6-12	699-702	for	abstract[39]	new[39]	_	_
6-13	703-713	laboratory	abstract[39]|event[41]	new[39]|giv[41]	_	_
6-14	714-723	diagnosis	abstract[39]|event[41]	new[39]|giv[41]	_	_
6-15	724-726	of	abstract[39]|event[41]	new[39]|giv[41]	_	_
6-16	727-734	malaria	abstract[39]|event[41]|abstract	new[39]|giv[41]|giv	coref	6-49[53_0]
6-17	735-738	has	_	_	_	_
6-18	739-743	some	abstract[43]	new[43]	_	_
6-19	744-755	limitations	abstract[43]	new[43]	_	_
6-20	756-757	,	_	_	_	_
6-21	758-764	namely	abstract[44]	new[44]	_	_
6-22	765-766	:	abstract[44]	new[44]	_	_
6-23	767-768	(	abstract[44]	new[44]	_	_
6-24	769-770	i	abstract[44]	new[44]	_	_
6-25	771-772	)	abstract[44]	new[44]	_	_
6-26	773-776	low	abstract[46]	new[46]	_	_
6-27	777-785	antibody	substance|abstract[46]	giv|new[46]	_	_
6-28	786-792	titres	abstract[46]	new[46]	_	_
6-29	793-802	presented	_	_	_	_
6-30	803-805	by	_	_	_	_
6-31	806-817	individuals	person[47]	giv[47]	ana	7-16[0_47]
6-32	818-820	in	person[47]	giv[47]	_	_
6-33	821-824	the	person[47]|abstract[48]	giv[47]|new[48]	_	_
6-34	825-830	acute	person[47]|abstract[48]	giv[47]|new[48]	_	_
6-35	831-836	phase	person[47]|abstract[48]	giv[47]|new[48]	_	_
6-36	837-839	of	person[47]|abstract[48]	giv[47]|new[48]	_	_
6-37	840-849	infection	person[47]|abstract[48]|abstract[49]	giv[47]|new[48]|giv[49]	coref	6-62[0_49]
6-38	850-851	;	person[47]|abstract[48]|abstract[49]	giv[47]|new[48]|giv[49]	_	_
6-39	852-853	(	person[47]|abstract[48]|abstract[49]|abstract[52]	giv[47]|new[48]|giv[49]|new[52]	coref	14-27[141_52]
6-40	854-856	ii	person[47]|abstract[48]|abstract[49]|abstract|abstract[52]	giv[47]|new[48]|giv[49]|new|new[52]	_	_
6-41	857-858	)	person[47]|abstract[48]|abstract[49]|abstract[52]	giv[47]|new[48]|giv[49]|new[52]	_	_
6-42	859-863	many	person[47]|abstract[48]|abstract[49]|abstract[52]	giv[47]|new[48]|giv[49]|new[52]	_	_
6-43	864-874	Plasmodium	person[47]|abstract[48]|abstract[49]|substance|abstract[52]	giv[47]|new[48]|giv[49]|new|new[52]	coref	6-59
6-44	875-877	sp	person[47]|abstract[48]|abstract[49]|abstract[52]	giv[47]|new[48]|giv[49]|new[52]	_	_
6-45	878-879	.	_	_	_	_
6-46	880-883	are	_	_	_	_
6-47	884-892	involved	_	_	_	_
6-48	893-895	in	_	_	_	_
6-49	896-901	human	abstract[53]	giv[53]	coref	6-86[0_53]
6-50	902-909	malaria	abstract[53]	giv[53]	_	_
6-51	910-911	;	_	_	_	_
6-52	912-913	(	_	_	_	_
6-53	914-917	iii	_	_	_	_
6-54	918-919	)	_	_	_	_
6-55	920-929	different	abstract[54]	new[54]	_	_
6-56	930-942	evolutionary	abstract[54]	new[54]	_	_
6-57	943-948	forms	abstract[54]	new[54]	_	_
6-58	949-951	of	abstract[54]	new[54]	_	_
6-59	952-962	Plasmodium	abstract[54]|substance	new[54]|giv	coref	14-27
6-60	963-967	spp.	abstract[54]	new[54]	_	_
6-61	968-974	during	abstract[54]	new[54]	_	_
6-62	975-984	infection	abstract[54]|abstract|animal[57]	new[54]|giv|giv[57]	coref|coref|coref|coref	6-77|6-86[68_57]|6-77|6-86[68_57]
6-63	985-988	and	abstract[54]|animal[57]	new[54]|giv[57]	_	_
6-64	989-993	life	abstract[54]|animal[57]|abstract|time[59]	new[54]|giv[57]|new|new[59]	_	_
6-65	994-999	cycle	abstract[54]|animal[57]|time[59]	new[54]|giv[57]|new[59]	_	_
6-66	1000-1001	;	_	_	_	_
6-67	1002-1005	and	_	_	_	_
6-68	1006-1007	(	_	_	_	_
6-69	1008-1010	iv	person	new	_	_
6-70	1011-1012	)	_	_	_	_
6-71	1013-1022	different	_	_	_	_
6-72	1023-1033	resistance	abstract	new	_	_
6-73	1034-1037	and	_	_	_	_
6-74	1038-1052	susceptibility	abstract|object[63]	new|new[63]	_	_
6-75	1053-1061	profiles	object[63]	new[63]	_	_
6-76	1062-1068	during	object[63]	new[63]	_	_
6-77	1069-1078	infection	object[63]|abstract	new[63]|giv	_	_
6-78	1079-1080	,	_	_	_	_
6-79	1081-1084	and	_	_	_	_
6-80	1085-1097	consequently	object[66]	new[66]	_	_
6-81	1098-1100	in	object[66]	new[66]	_	_
6-82	1101-1104	the	object[66]	new[66]	_	_
6-83	1105-1113	immunity	abstract|object[66]	new|new[66]	_	_
6-84	1114-1121	profile	object[66]	new[66]	_	_
6-85	1122-1129	against	object[66]	new[66]	_	_
6-86	1130-1137	malaria	object[66]|abstract|animal[68]	new[66]|giv|giv[68]	coref|coref|coref|coref	7-8|13-8[128_68]|7-8|13-8[128_68]
6-87	1138-1147	parasites	object[66]|animal[68]	new[66]|giv[68]	_	_
6-88	1148-1149	.	_	_	_	_

#Text=Associations among antibodies against parasite antigens and malaria risk areas are not always consistent ; some may depend on parasite antigens and other considerations may be due to the endemic areas of malaria .
7-1	1150-1162	Associations	abstract[69]	new[69]	_	_
7-2	1163-1168	among	abstract[69]	new[69]	_	_
7-3	1169-1179	antibodies	abstract[69]|substance[70]	new[69]|giv[70]	coref	8-9[0_70]
7-4	1180-1187	against	abstract[69]|substance[70]	new[69]|giv[70]	_	_
7-5	1188-1196	parasite	abstract[69]|substance[70]|animal|substance[72]	new[69]|giv[70]|new|giv[72]	coref|coref|coref|coref	7-20|7-20[78_72]|7-20|7-20[78_72]
7-6	1197-1205	antigens	abstract[69]|substance[70]|substance[72]	new[69]|giv[70]|giv[72]	_	_
7-7	1206-1209	and	abstract[69]|substance[70]|substance[72]	new[69]|giv[70]|giv[72]	_	_
7-8	1210-1217	malaria	abstract[69]|substance[70]|substance[72]|abstract|place[75]	new[69]|giv[70]|giv[72]|giv|new[75]	coref|coref|coref|coref	7-29[80_75]|7-33|7-29[80_75]|7-33
7-9	1218-1222	risk	abstract[69]|substance[70]|substance[72]|abstract|place[75]	new[69]|giv[70]|giv[72]|new|new[75]	coref	10-19[103_0]
7-10	1223-1228	areas	abstract[69]|substance[70]|substance[72]|place[75]	new[69]|giv[70]|giv[72]|new[75]	_	_
7-11	1229-1232	are	_	_	_	_
7-12	1233-1236	not	_	_	_	_
7-13	1237-1243	always	_	_	_	_
7-14	1244-1254	consistent	_	_	_	_
7-15	1255-1256	;	_	_	_	_
7-16	1257-1261	some	person	giv	_	_
7-17	1262-1265	may	_	_	_	_
7-18	1266-1272	depend	_	_	_	_
7-19	1273-1275	on	_	_	_	_
7-20	1276-1284	parasite	person|substance[78]	giv|giv[78]	coref|coref	8-11[0_78]|8-11[0_78]
7-21	1285-1293	antigens	substance[78]	giv[78]	_	_
7-22	1294-1297	and	_	_	_	_
7-23	1298-1303	other	abstract[79]	new[79]	_	_
7-24	1304-1318	considerations	abstract[79]	new[79]	_	_
7-25	1319-1322	may	_	_	_	_
7-26	1323-1325	be	_	_	_	_
7-27	1326-1329	due	_	_	_	_
7-28	1330-1332	to	_	_	_	_
7-29	1333-1336	the	place[80]	giv[80]	_	_
7-30	1337-1344	endemic	place[80]	giv[80]	_	_
7-31	1345-1350	areas	place[80]	giv[80]	_	_
7-32	1351-1353	of	place[80]	giv[80]	_	_
7-33	1354-1361	malaria	place[80]|abstract	giv[80]|giv	ana	8-1
7-34	1362-1363	.	_	_	_	_

#Text=It should be considered that single responses of antibodies against antigens might be inadequate to for use as biomarkers and indicators of malaria transmission intensity .
8-1	1364-1366	It	abstract	giv	coref	8-23
8-2	1367-1373	should	_	_	_	_
8-3	1374-1376	be	_	_	_	_
8-4	1377-1387	considered	_	_	_	_
8-5	1388-1392	that	_	_	_	_
8-6	1393-1399	single	abstract[83]	new[83]	_	_
8-7	1400-1409	responses	abstract[83]	new[83]	_	_
8-8	1410-1412	of	abstract[83]	new[83]	_	_
8-9	1413-1423	antibodies	abstract[83]|substance	new[83]|giv	coref	14-15[137_0]
8-10	1424-1431	against	abstract[83]	new[83]	_	_
8-11	1432-1440	antigens	abstract[83]|substance	new[83]|giv	coref	14-24[139_0]
8-12	1441-1446	might	_	_	_	_
8-13	1447-1449	be	_	_	_	_
8-14	1450-1460	inadequate	_	_	_	_
8-15	1461-1463	to	_	_	_	_
8-16	1464-1467	for	_	_	_	_
8-17	1468-1471	use	abstract[86]	giv[86]	_	_
8-18	1472-1474	as	abstract[86]	giv[86]	_	_
8-19	1475-1485	biomarkers	abstract[86]	giv[86]	_	_
8-20	1486-1489	and	abstract[86]	giv[86]	_	_
8-21	1490-1500	indicators	abstract[86]	giv[86]	_	_
8-22	1501-1503	of	abstract[86]	giv[86]	_	_
8-23	1504-1511	malaria	abstract[86]|abstract|abstract[89]	giv[86]|giv|new[89]	coref|coref	10-21|10-21
8-24	1512-1524	transmission	abstract[86]|abstract|abstract[89]	giv[86]|giv|new[89]	_	_
8-25	1525-1534	intensity	abstract[86]|abstract[89]	giv[86]|new[89]	_	_
8-26	1535-1536	.	_	_	_	_

#Text=Other authors have shown that new serological biomarkers can more accurately estimate the recent exposure to P. falciparum not only of a community , but also for several communities .
9-1	1537-1542	Other	person[90]	new[90]	_	_
9-2	1543-1550	authors	person[90]	new[90]	_	_
9-3	1551-1555	have	_	_	_	_
9-4	1556-1561	shown	_	_	_	_
9-5	1562-1566	that	_	_	_	_
9-6	1567-1570	new	abstract[91]	new[91]	_	_
9-7	1571-1582	serological	abstract[91]	new[91]	_	_
9-8	1583-1593	biomarkers	abstract[91]	new[91]	_	_
9-9	1594-1597	can	_	_	_	_
9-10	1598-1602	more	_	_	_	_
9-11	1603-1613	accurately	_	_	_	_
9-12	1614-1622	estimate	_	_	_	_
9-13	1623-1626	the	abstract[92]	new[92]	_	_
9-14	1627-1633	recent	abstract[92]	new[92]	_	_
9-15	1634-1642	exposure	abstract[92]	new[92]	_	_
9-16	1643-1645	to	abstract[92]	new[92]	_	_
9-17	1646-1648	P.	abstract[92]|place|abstract[94]	new[92]|new|new[94]	coref|coref|coref|coref	10-25|10-23[106_94]|10-25|10-23[106_94]
9-18	1649-1659	falciparum	abstract[92]|abstract[94]	new[92]|new[94]	_	_
9-19	1660-1663	not	abstract[92]|abstract[94]	new[92]|new[94]	_	_
9-20	1664-1668	only	abstract[92]|abstract[94]|organization[95]	new[92]|new[94]|new[95]	_	_
9-21	1669-1671	of	abstract[92]|abstract[94]|organization[95]	new[92]|new[94]|new[95]	_	_
9-22	1672-1673	a	abstract[92]|abstract[94]|organization[95]	new[92]|new[94]|new[95]	_	_
9-23	1674-1683	community	abstract[92]|abstract[94]|organization[95]	new[92]|new[94]|new[95]	_	_
9-24	1684-1685	,	_	_	_	_
9-25	1686-1689	but	_	_	_	_
9-26	1690-1694	also	_	_	_	_
9-27	1695-1698	for	_	_	_	_
9-28	1699-1706	several	organization[96]	new[96]	_	_
9-29	1707-1718	communities	organization[96]	new[96]	_	_
9-30	1719-1720	.	_	_	_	_

#Text=In 2015 , approximately 3.2 billion people — nearly half of the world ’s population — were at risk of malaria , mainly by P. falciparum .
10-1	1721-1723	In	_	_	_	_
10-2	1724-1728	2015	time	new	_	_
10-3	1729-1730	,	_	_	_	_
10-4	1731-1744	approximately	person[99]	new[99]	appos	10-9[100_99]
10-5	1745-1748	3.2	person[99]	new[99]	_	_
10-6	1749-1756	billion	abstract|person[99]	new|new[99]	_	_
10-7	1757-1763	people	person[99]	new[99]	_	_
10-8	1764-1765	—	_	_	_	_
10-9	1766-1772	nearly	person[100]	giv[100]	_	_
10-10	1773-1777	half	person[100]	giv[100]	_	_
10-11	1778-1780	of	person[100]	giv[100]	_	_
10-12	1781-1784	the	person[100]|person[102]	giv[100]|new[102]	_	_
10-13	1785-1790	world	person[100]|place[101]|person[102]	giv[100]|new[101]|new[102]	_	_
10-14	1791-1793	’s	person[100]|place[101]|person[102]	giv[100]|new[101]|new[102]	_	_
10-15	1794-1804	population	person[100]|person[102]	giv[100]|new[102]	_	_
10-16	1805-1806	—	_	_	_	_
10-17	1807-1811	were	_	_	_	_
10-18	1812-1814	at	_	_	_	_
10-19	1815-1819	risk	abstract[103]	giv[103]	_	_
10-20	1820-1822	of	abstract[103]	giv[103]	_	_
10-21	1823-1830	malaria	abstract[103]|abstract	giv[103]|giv	coref	11-9
10-22	1831-1832	,	abstract[103]	giv[103]	_	_
10-23	1833-1839	mainly	abstract[103]|abstract[106]	giv[103]|giv[106]	coref	12-1[124_106]
10-24	1840-1842	by	abstract[103]|abstract[106]	giv[103]|giv[106]	_	_
10-25	1843-1845	P.	abstract[103]|place|abstract[106]	giv[103]|giv|giv[106]	coref	12-1
10-26	1846-1856	falciparum	abstract[103]|abstract[106]	giv[103]|giv[106]	_	_
10-27	1857-1858	.	_	_	_	_

#Text=After several decades of disease control campaigns , malaria persists as one of the most serious public health problems , not only in endemic countries , but also in non-endemic regions , where the number of cases of imported malaria via tourists and immigrants is on the rise .
11-1	1859-1864	After	_	_	_	_
11-2	1865-1872	several	time[107]	new[107]	_	_
11-3	1873-1880	decades	time[107]	new[107]	_	_
11-4	1881-1883	of	time[107]	new[107]	_	_
11-5	1884-1891	disease	time[107]|abstract|abstract[110]	new[107]|giv|new[110]	coref|coref	13-27[132_0]|13-27[132_0]
11-6	1892-1899	control	time[107]|abstract|abstract[110]	new[107]|new|new[110]	_	_
11-7	1900-1909	campaigns	time[107]|abstract[110]	new[107]|new[110]	_	_
11-8	1910-1911	,	_	_	_	_
11-9	1912-1919	malaria	abstract	giv	coref	11-39[119_0]
11-10	1920-1928	persists	_	_	_	_
11-11	1929-1931	as	_	_	_	_
11-12	1932-1935	one	abstract[112]	new[112]	coref	13-2[125_112]
11-13	1936-1938	of	abstract[112]	new[112]	_	_
11-14	1939-1942	the	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-15	1943-1947	most	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-16	1948-1955	serious	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-17	1956-1962	public	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-18	1963-1969	health	abstract[112]|abstract|abstract[114]	new[112]|new|new[114]	_	_
11-19	1970-1978	problems	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-20	1979-1980	,	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-21	1981-1984	not	abstract[112]|abstract[114]	new[112]|new[114]	_	_
11-22	1985-1989	only	abstract[112]|abstract[114]|place[115]	new[112]|new[114]|new[115]	_	_
11-23	1990-1992	in	abstract[112]|abstract[114]|place[115]	new[112]|new[114]|new[115]	_	_
11-24	1993-2000	endemic	abstract[112]|abstract[114]|place[115]	new[112]|new[114]|new[115]	_	_
11-25	2001-2010	countries	abstract[112]|abstract[114]|place[115]	new[112]|new[114]|new[115]	_	_
11-26	2011-2012	,	_	_	_	_
11-27	2013-2016	but	_	_	_	_
11-28	2017-2021	also	_	_	_	_
11-29	2022-2024	in	_	_	_	_
11-30	2025-2036	non-endemic	place[116]	new[116]	_	_
11-31	2037-2044	regions	place[116]	new[116]	_	_
11-32	2045-2046	,	_	_	_	_
11-33	2047-2052	where	_	_	_	_
11-34	2053-2056	the	abstract[117]	new[117]	_	_
11-35	2057-2063	number	abstract[117]	new[117]	_	_
11-36	2064-2066	of	abstract[117]	new[117]	_	_
11-37	2067-2072	cases	abstract[117]|abstract[118]	new[117]|new[118]	_	_
11-38	2073-2075	of	abstract[117]|abstract[118]	new[117]|new[118]	_	_
11-39	2076-2084	imported	abstract[117]|abstract[118]|abstract[119]	new[117]|new[118]|giv[119]	coref	13-9[0_119]
11-40	2085-2092	malaria	abstract[117]|abstract[118]|abstract[119]	new[117]|new[118]|giv[119]	_	_
11-41	2093-2096	via	abstract[117]|abstract[118]|abstract[119]	new[117]|new[118]|giv[119]	_	_
11-42	2097-2105	tourists	abstract[117]|abstract[118]|abstract[119]|person	new[117]|new[118]|giv[119]|new	_	_
11-43	2106-2109	and	abstract[117]|abstract[118]|abstract[119]	new[117]|new[118]|giv[119]	_	_
11-44	2110-2120	immigrants	abstract[117]|abstract[118]|abstract[119]|person	new[117]|new[118]|giv[119]|new	_	_
11-45	2121-2123	is	_	_	_	_
11-46	2124-2126	on	_	_	_	_
11-47	2127-2130	the	abstract[122]	new[122]	_	_
11-48	2131-2135	rise	abstract[122]	new[122]	_	_
11-49	2136-2137	.	_	_	_	_

#Text=P. falciparum
12-1	2138-2140	P.	place|abstract[124]	giv|giv[124]	coref|coref|coref|coref	14-41|14-41[145_124]|14-41|14-41[145_124]
12-2	2141-2151	falciparum	abstract[124]	giv[124]	_	_

#Text=is one the most lethal species of the malaria parasites that infect humans , and is responsible for the highest number of serious pathologies associated with the disease .
13-1	2152-2154	is	_	_	_	_
13-2	2155-2158	one	abstract[125]	giv[125]	_	_
13-3	2159-2162	the	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
13-4	2163-2167	most	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
13-5	2168-2174	lethal	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
13-6	2175-2182	species	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
13-7	2183-2185	of	abstract[125]|abstract[126]	giv[125]|new[126]	_	_
13-8	2186-2189	the	abstract[125]|abstract[126]|animal[128]	giv[125]|new[126]|giv[128]	_	_
13-9	2190-2197	malaria	abstract[125]|abstract[126]|abstract|animal[128]	giv[125]|new[126]|giv|giv[128]	coref	15-19
13-10	2198-2207	parasites	abstract[125]|abstract[126]|animal[128]	giv[125]|new[126]|giv[128]	_	_
13-11	2208-2212	that	_	_	_	_
13-12	2213-2219	infect	_	_	_	_
13-13	2220-2226	humans	person	new	_	_
13-14	2227-2228	,	_	_	_	_
13-15	2229-2232	and	_	_	_	_
13-16	2233-2235	is	_	_	_	_
13-17	2236-2247	responsible	_	_	_	_
13-18	2248-2251	for	_	_	_	_
13-19	2252-2255	the	abstract[130]	new[130]	_	_
13-20	2256-2263	highest	abstract[130]	new[130]	_	_
13-21	2264-2270	number	abstract[130]	new[130]	_	_
13-22	2271-2273	of	abstract[130]	new[130]	_	_
13-23	2274-2281	serious	abstract[130]|abstract[131]	new[130]|new[131]	_	_
13-24	2282-2293	pathologies	abstract[130]|abstract[131]	new[130]|new[131]	_	_
13-25	2294-2304	associated	_	_	_	_
13-26	2305-2309	with	_	_	_	_
13-27	2310-2313	the	abstract[132]	giv[132]	_	_
13-28	2314-2321	disease	abstract[132]	giv[132]	_	_
13-29	2322-2323	.	_	_	_	_

#Text=In this work , we performed a comparative analysis of the serological reactivity of total antimalarial antibodies obtained by a commercial ELISA using recombinant antigens from Plasmodium sp . , compared to an in-house ELISA , using crude extract of P. falciparum 3D7 .
14-1	2324-2326	In	_	_	_	_
14-2	2327-2331	this	abstract[133]	new[133]	_	_
14-3	2332-2336	work	abstract[133]	new[133]	_	_
14-4	2337-2338	,	_	_	_	_
14-5	2339-2341	we	person	acc	ana	15-3
14-6	2342-2351	performed	_	_	_	_
14-7	2352-2353	a	abstract[135]	new[135]	_	_
14-8	2354-2365	comparative	abstract[135]	new[135]	_	_
14-9	2366-2374	analysis	abstract[135]	new[135]	_	_
14-10	2375-2377	of	abstract[135]	new[135]	_	_
14-11	2378-2381	the	abstract[135]|abstract[136]	new[135]|new[136]	_	_
14-12	2382-2393	serological	abstract[135]|abstract[136]	new[135]|new[136]	_	_
14-13	2394-2404	reactivity	abstract[135]|abstract[136]	new[135]|new[136]	_	_
14-14	2405-2407	of	abstract[135]|abstract[136]	new[135]|new[136]	_	_
14-15	2408-2413	total	abstract[135]|abstract[136]|substance[137]	new[135]|new[136]|giv[137]	_	_
14-16	2414-2426	antimalarial	abstract[135]|abstract[136]|substance[137]	new[135]|new[136]|giv[137]	_	_
14-17	2427-2437	antibodies	abstract[135]|abstract[136]|substance[137]	new[135]|new[136]|giv[137]	_	_
14-18	2438-2446	obtained	_	_	_	_
14-19	2447-2449	by	_	_	_	_
14-20	2450-2451	a	abstract[138]	giv[138]	coref	14-33[142_138]
14-21	2452-2462	commercial	abstract[138]	giv[138]	_	_
14-22	2463-2468	ELISA	abstract[138]	giv[138]	_	_
14-23	2469-2474	using	_	_	_	_
14-24	2475-2486	recombinant	substance[139]	giv[139]	coref	15-6[149_139]
14-25	2487-2495	antigens	substance[139]	giv[139]	_	_
14-26	2496-2500	from	substance[139]	giv[139]	_	_
14-27	2501-2511	Plasmodium	substance[139]|substance|abstract[141]	giv[139]|giv|giv[141]	_	_
14-28	2512-2514	sp	substance[139]|abstract[141]	giv[139]|giv[141]	_	_
14-29	2515-2516	.	_	_	_	_
14-30	2517-2518	,	_	_	_	_
14-31	2519-2527	compared	_	_	_	_
14-32	2528-2530	to	_	_	_	_
14-33	2531-2533	an	abstract[142]	giv[142]	coref	15-30[155_142]
14-34	2534-2542	in-house	abstract[142]	giv[142]	_	_
14-35	2543-2548	ELISA	abstract[142]	giv[142]	_	_
14-36	2549-2550	,	_	_	_	_
14-37	2551-2556	using	_	_	_	_
14-38	2557-2562	crude	object[143]	new[143]	_	_
14-39	2563-2570	extract	object[143]	new[143]	_	_
14-40	2571-2573	of	object[143]	new[143]	_	_
14-41	2574-2576	P.	object[143]|place|abstract[145]	new[143]|giv|giv[145]	coref|coref|coref|coref	15-6[147_0]|15-9[0_145]|15-6[147_0]|15-9[0_145]
14-42	2577-2587	falciparum	object[143]|abstract[145]	new[143]|giv[145]	_	_
14-43	2588-2591	3D7	object[143]|abstract[145]	new[143]|giv[145]	_	_
14-44	2592-2593	.	_	_	_	_

#Text=Thus , we showed that several other P. falciparum antigens are equally important for the serological diagnosis of malaria , as well as some recombinant antigens commonly used in commercial ELISA .
15-1	2594-2598	Thus	_	_	_	_
15-2	2599-2600	,	_	_	_	_
15-3	2601-2603	we	person	giv	_	_
15-4	2604-2610	showed	_	_	_	_
15-5	2611-2615	that	_	_	_	_
15-6	2616-2623	several	place[147]|substance[149]	giv[147]|giv[149]	coref|coref	15-24[154_149]|15-24[154_149]
15-7	2624-2629	other	place[147]|substance[149]	giv[147]|giv[149]	_	_
15-8	2630-2632	P.	place[147]|substance[149]	giv[147]|giv[149]	_	_
15-9	2633-2643	falciparum	abstract|substance[149]	giv|giv[149]	_	_
15-10	2644-2652	antigens	substance[149]	giv[149]	_	_
15-11	2653-2656	are	_	_	_	_
15-12	2657-2664	equally	_	_	_	_
15-13	2665-2674	important	_	_	_	_
15-14	2675-2678	for	_	_	_	_
15-15	2679-2682	the	abstract[150]|event[151]	new[150]|giv[151]	_	_
15-16	2683-2694	serological	abstract[150]|event[151]	new[150]|giv[151]	_	_
15-17	2695-2704	diagnosis	abstract[150]|event[151]	new[150]|giv[151]	_	_
15-18	2705-2707	of	abstract[150]|event[151]	new[150]|giv[151]	_	_
15-19	2708-2715	malaria	abstract[150]|event[151]|abstract	new[150]|giv[151]|giv	_	_
15-20	2716-2717	,	event[151]	giv[151]	_	_
15-21	2718-2720	as	event[151]	giv[151]	_	_
15-22	2721-2725	well	event[151]	giv[151]	_	_
15-23	2726-2728	as	event[151]	giv[151]	_	_
15-24	2729-2733	some	event[151]|substance[154]	giv[151]|giv[154]	_	_
15-25	2734-2745	recombinant	event[151]|person|substance[154]	giv[151]|new|giv[154]	_	_
15-26	2746-2754	antigens	event[151]|substance[154]	giv[151]|giv[154]	_	_
15-27	2755-2763	commonly	_	_	_	_
15-28	2764-2768	used	_	_	_	_
15-29	2769-2771	in	_	_	_	_
15-30	2772-2782	commercial	abstract[155]	giv[155]	_	_
15-31	2783-2788	ELISA	abstract[155]	giv[155]	_	_
15-32	2789-2790	.	_	_	_	_
